English 
Complex regional pain syndrome (CRPS)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00
Complex regional pain syndrome (CRPS) is a chronic pain condition characterized by spontaneous and evoked regional pain, usually starting in a distal extremity, which is disproportionate in magnitude or duration to the typical pain course after similar tissue trauma. Current treatment for CRPS requires a multidisciplinary approach involving patient education, physical and occupational therapy, psychiatry and pain medicine specialists, along with pharmacological and surgical interventions. Unfortunately, the current available treatment options are generally considered to be ineffective and one-dimensional, as they only treat part of the disease. Emerging therapies like Soticlestat (Takeda / Ovid Therapeutics and Lanicemine (AstraZeneca / Biohaven Pharmaceuticals) is expected to generate more market share than other emerging therapies and have the potential to overcome the treatment barrier.
Description
Complex regional pain syndrome (CRPS; formerly known as RSD or reflex sympathetic dystrophy) is defined as a debilitating chronic pain condition characterized by severe pain along with sensory, autonomic, motor and trophic impairment often involving hyperalgesia and allodynia of the extremities.
Originally classified by the International Association for the Study of Pain (IASP) in 1994 and formally updated to accept the Budapest Criteria of 2003 due to the increased statistical measures and currently considered the most accepted diagnostic approach, the classification of CRPS brings about two different etiologies with differing presentations: a) CRPS type I (previously Reflex Sympathetic Dystrophy) develops after trauma or injury and does not involve a specific peripheral nerve and b) CRPS type II (previously Causalgia) develops after peripheral nerve injury. CRPS is more common in women but can occur in anyone at any age, peaking around the age of 40. It is rare in the elderly, who have less inflammation after injury, and in young children who heal so quickly and completely.
Complex regional pain syndrome – Prevalence (Epidemiology)
“The total prevalent cases in the G7 countries are anticipated to rise from 253,603 in 2018 to XXX by 2032 at a CAGR of XX% for the study period (2018–2032). The United States was estimated to have the highest prevalence of Complex regional pain syndrome (CRPS) cases in 2022.”
Complex region pain Syndrome – Current Market Size & Forecast Trends
Unfortunately, the current treatment options available are generally considered ineffective and unidimensional, which are treating only a part of the disease. At present, physical therapy and pharmacological interventions consisting of non-steroidal anti-inflammatory drugs (NSAID), corticosteroids have been used as first-line treatment for pain and inflammation associated with CRPS in both adults and pediatric patients. However, as patients proceed to second-line and third-line treatment, various side-effects such as weight gain, sleep disturbances, gastrointestinal problems, become a major treatment concern. Last-line of treatments consists of opioids which is rarely used in case of CRPS and surgical approaches such as spinal cord stimulators and ketamine, but they involve high-cost and huge treatment risks.
“There is only one effective treatment approved for complex regional pain syndrome in Italy with access to EU neighboring countries and also used off label in the United States. According to the experts, Neridronate is the right path towards an actual cure. If caught on time, in 80% of cases, CRPS actually disappears and none of the patients notices a return of the symptoms after the treatment. Ninety-seven percent of patients showed much improvement after Neridronate infusions.”
The Complex regional pain syndrome (CRPS) therapeutic market is expected to increase at a significant rate during the figure time frame, 2021 to 2030. In 2021, the market is developing at a consistent rate and the is relied upon to ascend over the projected horizon with the rise in adoption strategies by key market players. The therapy market is expected to experience high growth throughout our study period, increasing from 2017 to 2030 from USD XXX million to USD 0.95 billion, representing compound annual growth (CAGR) of XX%. Primary drivers of this growth will be the launch of the new drugs i.e., Neridronate/Nerixia (Abiogen Pharma/Grünenthal), Soticlestat (Takeda/Ovid Therapeutics), Lanicemine (AstraZeneca/Biohaven Pharmaceuticals) and Low dose naltrexone (Soin Therapeutics).
Report Highlights
- Complex regional pain syndrome (CRPS)– Current Market Trends
- Complex regional pain syndrome (CRPS)– Current & Forecasted Cases across the G7 Countries
- Complex regional pain syndrome (CRPS)– Market Opportunities and Sales Potential for Agents
- Complex regional pain syndrome (CRPS)– Patient-based Market Forecast to 2032
- Complex regional pain syndrome (CRPS)– Untapped Business Opportunities
- Complex regional pain syndrome (CRPS)– Product Positioning Vis-a-vis Competitors’ Products
- Complex regional pain syndrome (CRPS)– KOLs Insight
Additional information
| Price | 2-3 User License, Enterprise License, Single User License, Site License |
|---|
Table of Contents
- Executive Summary
- Key Findings
- Complex regional pain syndrome (CRPS) Disease Background
- Complex regional pain syndrome (CRPS) Definition
- Symptoms & Causes
- Classifications
- Stages
- Pathophysiology
- Diagnosis & Diagnostic Criteria
- Differential Diagnosis
- Epidemiology and Patient Populations
- Key Findings
- Methods and data Sources
- Country Specific Prevalent Population with Complex regional pain syndrome (CRPS) (US, Germany, France, Italy, Spain, UK, and Japan)
- Country Type-Specific Cases with Complex regional pain syndrome (CRPS) (CRPS-I & CRPS-II)
- Country Specific Diagnosed and Treatable Cases of Complex regional pain syndrome (CRPS)
- Key Sources for Complex regional pain syndrome (CRPS) Epidemiology and Model Parameters
- United States
- United States Prevalent Population with Complex regional pain syndrome (CRPS)
- United States Type-specific cases with Complex regional pain syndrome (CRPS) (CRPS-I & CRPS-II)
- United States Diagnosed and Treatable Cases of Complex regional pain syndrome (CRPS)
- Germany
- Germany Prevalent Population with Complex regional pain syndrome (CRPS)
- Germany Type-specific cases with Complex regional pain syndrome (CRPS) (CRPS-I & CRPS-II)
- Germany Diagnosed and Treatable Cases of Complex regional pain syndrome (CRPS)
- France
- France Prevalent Population with Complex regional pain syndrome (CRPS)
- France Type-specific cases with Complex regional pain syndrome (CRPS) (CRPS-I & CRPS-II)
- France Diagnosed and Treatable Cases of Complex regional pain syndrome (CRPS)
- Italy
- Italy Prevalent Population with Complex regional pain syndrome (CRPS)
- Italy Type-specific cases with Complex regional pain syndrome (CRPS) (CRPS-I & CRPS-II)
- Italy Diagnosed and Treatable Cases of Complex regional pain syndrome (CRPS)
- Spain
- United States
-
-
-
- Spain Prevalent Population with Complex regional pain syndrome (CRPS)
- Spain Type-specific cases with Complex regional pain syndrome (CRPS) (CRPS-I & CRPS-II)
- Spain Diagnosed and Treatable Cases of Complex regional pain syndrome (CRPS)
- United Kingdom
- United Kingdom Prevalent Population with Complex regional pain syndrome (CRPS)
- United Kingdom Type-specific cases with Complex regional pain syndrome (CRPS) (CRPS-I & CRPS-II)
- United Kingdom Diagnosed and Treatable Cases of Complex regional pain syndrome (CRPS)
- Japan
- Japan Prevalent Population with Complex regional pain syndrome (CRPS)
- Japan Type-specific cases with Complex regional pain syndrome (CRPS) (CRPS-I & CRPS-II)
- Japan Diagnosed and Treatable Cases of Complex regional pain syndrome (CRPS)
-
-
- Current Therapies and Medical Practice
- Treatments & Medical Practices
- Pharmacological Approach
- UK Pharmacological Guidelines
- Non-Pharmacological Approach
- Surgical Approach
- Treatment Paradigm
- Marketed Drug
- Neridronate (Abiogen Pharma/Grünenthal) (Marketed in Italy)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- Neridronate (Abiogen Pharma/Grünenthal) (Marketed in Italy)
- Unmet Needs
- Emerging Therapies
- Pipeline Overview
- Therapeutic Developments Pipeline for Complex regional pain syndrome (CRPS)
- Product Analysis
- Soticlestat (Takeda/Ovid Therapeutics)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- Lanicemine (AstraZeneca/Biohaven Pharmaceutical)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- Ketamine (iX Biopharma)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- PPP-001 (Tetra Bio-Pharma)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- Low dose naltrexone (Soin Therapeutics)
- Product Profile
- Ketamine (Bexson Biomedical)
- Product Profile
- Soticlestat (Takeda/Ovid Therapeutics)
- Product Analysis
- Complex regional pain syndrome (CRPS)- Pricing & Reimbursement
- Future Treatment Paradigm
- Complex regional pain syndrome (CRPS) Competitor Landscape and Approvals Anticipated
- Future Treatment Algorithms and Competitor Positioning
- Key Data Summary for Emerging Treatment
- Annual Cost of Current & Emerging Therapies
- Market Outlook
- Key Findings
- Country Specific Market Forecast to 2032
- Sales of Drugs to Treat Complex regional pain syndrome (CRPS) in the Major Pharmaceutical Markets, 2022-2032
- Patient Share of Complex regional pain syndrome (CRPS) Therapies and by Drug
- Market Forecast by Country
- United States
- United States Market for Complex regional pain syndrome (CRPS) 2022-2032 (USD Million)
- United States Market for Complex regional pain syndrome (CRPS) by Therapies 2022-2032 (USD Million)
- Germany
- Germany Market for Complex regional pain syndrome (CRPS) 2022-2032 (USD Million)
- Germany Market for Complex regional pain syndrome (CRPS) by Therapies 2022-2032 (USD Million)
- France
- France Market for Complex regional pain syndrome (CRPS) 2022-2032 (USD Million)
- France Market for Complex regional pain syndrome (CRPS) by Therapies 2022-2032 (USD Million)
- Italy
- Italy Market for Complex regional pain syndrome (CRPS) 2022-2032 (USD Million)
- Italy Market for Complex regional pain syndrome (CRPS) by Therapies 2022-2032 (USD Million)
- Spain
- Spain Market for Complex regional pain syndrome (CRPS) 2022-2032 (USD Million)
- Spain Market for Complex regional pain syndrome (CRPS) by Therapies 2022-2032 (USD Million)
- United Kingdom
- United Kingdom Market for Complex regional pain syndrome (CRPS) 2022-2032 (USD Million)
- United Kingdom Market for Complex regional pain syndrome (CRPS) by Therapies 2022-2032 (USD Million)
- Japan
- Japan Market for Complex regional pain syndrome (CRPS) 2022-2032 (USD Million)
- Japan Market for Complex regional pain syndrome (CRPS) by Therapies 2022-2032 (USD Million)
- United States
- Market Drivers and Constraints
- What Factors Are Driving the Market for Complex regional pain syndrome (CRPS)?
- What Factors Are Constraining the Market for Complex regional pain syndrome (CRPS)?
- Appendix
Sample Enquiry
Related products
-
Anti-Neutralizing Antibodies (NAbs) Gene Therapies-Pipeline Analytics 2022
$2,700.00 – $8,100.00Select optionsAnti-Neutralizing Antibodies (NAbs) Gene Therapies report covers the Anti-Neutralizing Antibodies (NAbs) Gene Therapies market opportunity providing Key Competitive Analysis, 20+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partner as well as Clinical Partner. Reports covers pipeline product analysis by stage of development, competitive landscape by phases, companies, therapy area and indication by phases. NAbs inhibitor’s reports add a value in terms of providing the description of clinical stage product with respect to their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers and challenges.
-
Corticobasal Syndrome (CBS) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsCorticobasal syndrome (CBS) is characterized by lowest clinical diagnostic accuracy, with the highest clinical presentation found in corticobasal degeneration (CBD). Current Corticobasal syndrome (CBS) treatment is limited to levodopa, commonly prescribed medication for the treatment of Parkinson’s disease. Thus, there is a huge unmet need for a medical treatment to improve the quality of life. Emerging therapies like Rho-kinase inhibitor- Fasudil (Woolsey Pharmaceuticals) have the potential to overcome the treatment barrier. Corticobasal syndrome market size will reflect high growth from 2025-2030 due to launch of Fausdil (Woolsey) in the market from 2025 year.
-
Metastatic Ovarian Cancer (mOC)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsThe Metastatic Ovarian Cancer (mOC) market is relatively large with highest market share holding drugs in 2022 i.e., Olaparib and Niraparib. By 2032, the market is expected to change due to the loss of patents of the current therapies and the uptake and launch of new therapies. In a mOC treatment setting, the Olaparib will consistently perform and will grasp the highest market share followed by other emerging drugs. The sales of the emerging therapies for the treatment of mOC in the study countries (United States, France, Germany, Italy, Spain, United Kingdom and Japan) will experience high growth over the 2018-2032 study period, adding a value estimated at a total market of $ 5.3 billion by 2032.
-
ER+/HER2- Metastatic Breast Cancer (mBC)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsThe ER + / HER2- metastatic breast cancer (mBC) market is relatively large with the highest market share holding CDK4 / 6 drugs, e.g. Pfizer’s Ibrance (palbociclib), Novartis’s Kisqali (ribociclib) and Eli Lilly’s Verzenio (abemaciclib). By 2032, these drugs will continue to hold the largest share of the market, but we also expect the market to expand with the addition of new oral SERDs/SARMs/SERMs that will take a combined share of 19.1%, antibody drug conjugates with a share of the 2.9% and AKT inhibitors with a 2.6% share. The sales of the emerging therapies for the treatment of ER+/HER2- mBC in the study countries (United States, France, Germany, Italy, Spain, United Kingdom and Japan) will experience high growth over the 2022-2032 study period, adding a value estimated at a total market of $ 5.6 billion by 2032.